Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind Long-term Study Comparing the Efficacy and Safety of Olanzapine Versus Haloperidol in Patients With Schizophrenia Previously Stabilized With Conventional Antipsychotic Treatment

NCT00191555 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind Long-term Study Comparing the Efficacy and Safety of Olanzapine Versus Haloperidol in Patients With Schizophrenia Previously Stabilized With Conventional Antipsychotic Treatment
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2003
Completion date
May 31, 2006
Enrollment
360
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia